10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.
Breast Cancer
The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment., 1 visit
To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer, 1 Visit|To analyse CHD management patterns according to defined 10-year CHD risk categories, 1 Visit|To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk, 1 Visit
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.